Track: Precision Onco-Urology

Precision Onco-Urology integrates molecular science with clinical decision-making to improve the management of urological malignancies such as prostate, bladder, and renal cancers. These cancers are driven by genetic mutations, epigenetic dysregulation, and altered signaling pathways, contributing to tumor heterogeneity and variable treatment responses. This session highlights advances in genomic profiling, biomarker discovery, and molecular diagnostics that enable patient stratification and personalized therapies. Key oncogenes, tumor suppressor genes, genomic instability, and epigenetic mechanisms will be discussed, along with emerging targeted and immunotherapeutic strategies. The session emphasizes translational research to enhance precision-based diagnosis and individualized treatment in urological oncology.

Molecular Basis of Urological Cancers focuses on the cellular and molecular mechanisms driving urological cancers. It examines abnormal cell signaling, dysregulated cell cycle control, and resistance to apoptosis. Understanding these fundamental changes helps identify therapeutic targets and provides insight into tumor initiation, progression, and metastasis in urological malignancies.

Genomic Alterations and Biomarkers Genomic alterations such as point mutations, copy number variations, and gene fusions play a critical role in urological cancers. This section discusses key biomarkers used for diagnosis, prognosis, and therapy selection, including genomic profiling tools that enable risk stratification and personalized treatment approaches.

Tumor Suppressor Genes and Oncogenes explores the role of oncogenes and tumor suppressor genes such as TP53, PTEN, BRCA, and VHL. Mutations in these genes disrupt normal cellular regulation, promoting uncontrolled growth. Understanding their function is essential for predicting disease behavior and identifying targeted therapeutic options.

Epigenetic Regulation in Onco-Urology Epigenetic mechanisms, including DNA methylation and histone modification, influence gene expression without altering DNA sequences. This section highlights how epigenetic dysregulation contributes to urological cancer development and how epigenetic therapies may reverse abnormal gene expression patterns.

Targeted and Personalized Therapies focuses on therapies designed to target specific molecular abnormalities, including kinase inhibitors, PARP inhibitors, and immunotherapies. Personalized treatment strategies based on genomic data improve efficacy, reduce toxicity, and represent a major advancement in urological cancer management.

Translational and Clinical Applications, bridges basic research and clinical practice, emphasizing how molecular discoveries translate into real-world patient care. It includes clinical trials, precision diagnostics, and implementation challenges, highlighting the future direction of precision medicine in onco-urology.

4th International Conference on Cancer and Breast Cancer Treatment

Track: Precision Onco-Urology

Scientific Highlights

Organization Location

Mail us at

Our Social Presence

Call us at